Nolvadex 20mg (Tamoxifen) is a selective estrogen receptor modulator (SERM) used to block estrogen activity in certain tissues and support the treatment of estrogen sensitive conditions. Each pack contains 50 tablets.
Format50 Tablets
Concentration20mg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Tamoxifen Citrate, widely known by its pharmaceutical brand name Nolvadex, is a selective estrogen receptor modulator (SERM) with one of the most extensively documented clinical histories of any pharmaceutical compound. FDA approved since 1977 for breast cancer treatment and remaining among the most prescribed and researched SERMs in oncology and endocrinology literature across nearly five decades of continuous clinical investigation. F40 Biotech’s formulation delivers 20mg per tablet in a 50 count format, consistent with the concentration most commonly referenced in both oncological and HPG axis restoration research literature.
Tamoxifen’s SERM activity is defined by its tissue selective estrogen receptor interaction, acting as an estrogen antagonist in breast tissue and the hypothalamic pituitary axis while exerting partial estrogen agonist activity in other tissue sites including bone, liver, and endometrial tissue. This tissue selectivity is the pharmacological characteristic that distinguishes Tamoxifen’s research profile from Clomiphene and Enclomiphene within CSD’s SERM range. Where Clomiphene’s HPG axis stimulation is driven primarily by hypothalamic estrogen antagonism, Tamoxifen’s antagonist activity at the pituitary level is particularly well documented. Blocking estrogen’s suppressive effect on gonadotropin secretion through a slightly different receptor interaction profile that has generated comparative SERM research into the differential HPG axis stimulation characteristics of the two compounds at equivalent doses.
Tamoxifen’s metabolic pathway is a research relevant pharmacological characteristic that distinguishes it from other SERMs. Tamoxifen is a prodrug, requiring hepatic CYP2D6 enzyme conversion to its active metabolite Endoxifen, which carries substantially higher estrogen receptor binding affinity than the parent compound. This CYP2D6 dependent activation makes Tamoxifen research particularly relevant in studies examining pharmacogenomic variability, drug interaction effects on SERM activity, and the relationship between metabolizer status and clinical outcomes. Research dimension that single isomer SERMs like Enclomiphene and direct acting compounds like Anastrozole do not share.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks a comprehensive SERM and estrogen management range: Tamoxifen, Clomiphene, Enclomiphene, and Anastrozole; covering selective receptor modulation, pure isomer HPG stimulation, and aromatase inhibition from a single verified Canadian supplier for complete estrogen regulation research coverage. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Clomiphene and HCG in comparative SERM and HPG axis restoration studies. Browse CSD’s full PCT range for complete sourcing.
Nolvadex is a brand name for tamoxifen citrate, a prescription selective estrogen receptor modulator (SERM). Tamoxifen interacts with estrogen receptors in a tissue selective manner and is particularly known for blocking estrogen activity in breast tissue. Each tablet provides 20mg of tamoxifen, with 50 tablets supplied per package.
Tamoxifen is used in the treatment of estrogen receptor positive breast cancer, including certain early and metastatic breast cancers. It is also used following treatment of ductal carcinoma in situ (DCIS) to reduce the risk of invasive breast cancer and may be prescribed to reduce breast cancer incidence in certain women at elevated risk.
Tamoxifen binds to estrogen receptors and changes how estrogen responsive genes are activated. In breast tissue it primarily acts as an estrogen antagonist, limiting estrogen driven signaling that can promote the growth of hormone sensitive breast cancer cells. Its effects differ between tissues, which is why it is classified as a selective estrogen receptor modulator rather than a pure estrogen blocker.
Tamoxifen primarily works by binding to estrogen receptors and altering estrogen signaling. Aromatase inhibitors such as anastrozole, letrozole, and exemestane instead reduce the body's production of estrogen by targeting the aromatase enzyme. Both approaches can reduce estrogen related signaling, but they act through fundamentally different mechanisms.
Tamoxifen has important risks that require medical supervision, including venous thromboembolism such as deep vein thrombosis and pulmonary embolism, stroke, and changes to the endometrium including an increased risk of endometrial cancer. Other adverse effects can include hot flashes, menstrual changes, and visual or ocular problems. The balance of benefits and risks depends on the patient's indication and individual medical history.
![PRAMIPEXOLE 1MG X 100 [PARKINSON'S]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/09/PRAMIPEXOLE-1-X-100-300x300.webp)
![RALOXIFENE 60MG X 30 [BONE HEALTH]](https://www.canadasteroiddepot.is/wp-content/uploads/2024/11/RALOXIFENE-60-X-30-300x300.webp)
